Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for EVEROLIMUS
- Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
- Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations
- Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Study of Ribociclib and Everolimus in HGG and DIPG
- Everolimus Aging Study
- Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
- P2Y12 Inhibitor-based SAPT Following 1-month DAPT Versus Conventional DAPT After PCI With Biofreedom Ultra Drug-coated Stent for Unprotected Left Main Disease (ULTRA-LM)
- Adjunctive Everolimus Treatment of Refractory Epilepsy
- SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
- Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma
- ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
- Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
- Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
- Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
- DAPAgliflozin for Renal Protection in Heart Transplant Recipients
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- A Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
- Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
- Everolimus Trial in Laryngotracheal Stenosis
- Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
- Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
- CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4
- Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
- Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
- Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
- Comparison of Safety and Efficacy of de Novo Everolimus
- DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
- A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
- Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients
- Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)
- AZD9833 China PK Study
- Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- Sirolimus for Retinal Astrocytic Hamartoma
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient
- Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021)
- Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.
- Glutamine PET Imaging in LAM
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
- Cemiplimab in AlloSCT/SOT Recipients With CSCC
- Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
- Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
- Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function
- Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
- A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
- Immune Monitoring to Facilitate Belatacept Monotherapy
- Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
- Sintilimab in FH-deficient Renal Cell Carcinoma
- Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
- Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
- Treg Modulation With CD28 and IL-6 Receptor Antagonists
- Everolimus Monotherapy as Immunosuppression After Liver Transplant
- Azithromycin a Treatment for Pulmonary Sarcoidosis
- CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction
- Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
- A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
- XIENCE 28 USA Study
- FUSCC Refractory TNBC Umbrella (FUTURE)
- RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients
- Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
- Itacitinib + Everolimus in Hodgkin Lymphoma
- A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
- The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
- Liver Transplantation With Tregs at UCSF
- A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
- Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
- Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
- Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency
- Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy
- Liver Transplantation With Tregs at MGH
- Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
- Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
- Acetyl Salicylic Elimination Trial: The ASET Pilot Study
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
- Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
- Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
- Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants
- Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
- Testosterone in Metastatic Renal Cell Carcinoma Patients
- A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
- XIENCE 28 Global Study
- Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
- Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
- Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
- A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
- Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
- Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
- A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients
- Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient
- Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
- Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event
- XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
- MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
- Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.
- A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
- Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
- Open-label Study on Treatment of Primary Aldosteronism With Everolimus
- Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
- ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With Renal Cell Carcinoma (RCC)
- Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
- UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
- Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
- Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT
- CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
- Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen
- A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
- Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
- A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
- CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
- Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
- A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
- RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
- LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
- Non Culprit Lesion Study
- Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
- Circulating Tumor Cells and Tumor DNA in HCC and NET
- Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study
- TB Host Directed Therapy
- Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
- Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients
- A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
- Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
- De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study
- A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
- Palbociclib With Everolimus + Exemestane In BC
- SCHEDULE Follow Up Visit 5-7 yr
- Topical Everolimus in Patients With Tuberous Sclerosis Complex
- Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
- Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
- Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)
- Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
- A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
- Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
- Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation
- Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
- MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
- Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib
- Treg Therapy in Subclinical Inflammation in Kidney Transplantation
- Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
- Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
- Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study
- Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
- Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
- EVOLVE Short DAPT Study
- A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
- Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
- Study of the Combination of CM082 With Everolimus in Patients With mRCC
- Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
- Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance
- Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis
- Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
- Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
- Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
- Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients
- Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
- Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study
- COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
- PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
- Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
- Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
- A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
- Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls
- Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
- Safety and Durability of Sirolimus for Treatment of LAM
- Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant
- Phase I Trial of RO5126766 Alone and in Combination With Everolimus
- Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
- Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
- Dose EScalation Induction of EvERolimus
- Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT
- Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
- Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
- Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301
- Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
- Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function
- Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
- Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
- Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic A
- Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
- Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
- Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors
- Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
- A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
- Xience Versus Synergy in Left Main PCI
- Comparison of Biomatrix and Orsiro Drug Eluting Stent
- Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
- Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
- Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
- Phase II Study of Everolimus Beyond Progression
- OPALINE : A Study Of Morbidity And Mortality At 2 Years
- Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
- Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
- Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
- Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET)
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
- Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
- Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
- Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
- A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
- Molecular Phenotype Changes and Personalized Treatment for CRPC
- An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis
- Everolimus for Cancer With TSC1 or TSC2 Mutation
- Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
- Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
- Everolimus for Children With Recurrent or Progressive Ependymoma
- Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
- Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
- N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
- LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
- S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
- Regimen Optimization Study
- The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
- Belatacept for Renal Transplant Recipients With Delayed Graft Function
- Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
- BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
- REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
- Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
- Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
- ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
- Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
- Novartis Everolimus Transition
- MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation
- Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
- Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
- Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
- Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
- Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
- Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
- Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients
- Safety of Simvastatin in LAM and TSC
- A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
- Mesenchymal Stromal Cell Therapy in Renal Recipients
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
- Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
- Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
- A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
- Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients
- DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
- Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
- Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women
- Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
- Everolimus With and Without Temozolomide in Adult Low Grade Glioma
- Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer
- Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
- Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
- A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study
- Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
- A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas
- Everolimus Post Orthotopic Liver Transplant
- Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
- Comparing Everolimus and Sirolimus in Renal Transplant Recipients
- Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
- A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
- Influence of Exceptional Patient Characteristics on Everolimus Exposure
- Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
- Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.
- Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction
- EVESOR: a Phase 1 Trial of Everolimus and Sorafenib
- NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
- Rapalogues for Autism Phenotype in TSC: A Feasibility Study
- Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients
- Role of Everolimus in Highly Sensitized Patients
- Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria
- Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
- Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
- Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer
- Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
- A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
- Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
- A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
- Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
- Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
- Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
- Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients
- RAD001 in Advanced Sarcoma
- MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
- Myfortic in High MELD Liver Transplantation
- Rapid Activity of Platelet Inhibitor Drugs Study 2
- Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
- Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma
- The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium
- A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
- A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
- Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
- A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer
- 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
- Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
- Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
- VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
- Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
- A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.
- Pharmacokinetic of Everolimus and Atorvastatin Co-administration
- Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane
- DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES)
- An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
- PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
- Sequential Therapy in Metastatic Renal Cell Carinoma
- Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
- Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
- Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
- The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
- Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation
- Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
- Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
- Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
- Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
- A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
- Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
- Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population
- SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
- Short and Optimal Duration of Dual Antiplatelet Therapy Study
- Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
- Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors
- Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
- Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
- Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
- Everolimus in Treating Cutaneous T-cell Lymphoma
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
- The Everolimus-Transplant Exit Strategy Trial (E-TEST)
- Renal Transplantation in the Elderly - nEverOld Study
- Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
- Exemestane-RAD001-Metformin
- 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer
- SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
- A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients
- Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
- Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
- Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
- Study of Everolimus in de Novo Renal Transplant Recipients
- A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus
- Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
- Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
- Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)
- An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Adv
- A Prospective, Open Label Study of CERtican in KIdney Transplantation
- Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
- PROMUS Element Plus US Post-Approval Study
- Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
- Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
- Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET
- Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
- A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)
- 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
- Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise
- Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients
- Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
- Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
- Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
- Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling
- Controlled Level EVERolimus in Acute Coronary Syndromes
- Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma
- Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
- The Rosuvastatin In TrAnsplant Recipients Study
- Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
- Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
- Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
- PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)
- Rapid Activity of Platelet Inhibitor Drugs Study
- Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
- PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood
- The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease
- Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
- The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)
- Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
- Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
- Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
- Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
- RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression
- Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
- Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity
- A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
- Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients
- Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
- Everolimus in Refractory Testicular Germ Cell Cancer
- Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
- Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults
- BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
- Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
- Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
- Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
- Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
- Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
- Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
- Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study
- Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
- Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
- A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
- Everolimus in de Novo Kidney Transplant Recipients
- Rotating Pazopanib and Everolimus to Avoid Resistance
- Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients
- Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
- Efficacy of Certican® in Combination With Myfortic® in Renal
- Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy
- Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
- Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
- Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
- Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
- Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
- Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
- Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
- 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
- Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
- Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors
- Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery
- Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
- The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT)
- Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
- RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
- Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
- Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer
- De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction
- A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
- Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
- Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
- Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
- Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant
- Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
- A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
- Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
- A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
- Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation
- Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
- Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
- A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
- Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
- Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen
- Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
- SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
- Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
- Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
- RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
- RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
- A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
- Temsirolimus-RCC-imaging
- Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
- Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
- Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
- IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
- Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
- Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
- Study of Everolimus (RAD001) in Combination With Lenalidomide
- Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
- A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer
- Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
- Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
- First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
- A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
- RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
- Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
- Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
- Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
- Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
- An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens
- A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
- Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
- Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome
- Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
- 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
- Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer
- Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)
- Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
- A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
- Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
- Everolimus and LongActing Octreotide Trial in Polycystic Livers
- A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization
- Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
- Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients
- Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
- Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
- Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
- A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
- Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
- RAD001 Plus Carboplatin in Breast Cancer Patients
- Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
- Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
- Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
- A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
- Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
- Everolimus Versus Placebo in Head and Neck Cancer
- Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
- Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers
- XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
- A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)
- Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or
- Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
- Everolimus and Capecitabine in Patients With Advanced Malignancy
- Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer
- Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
- Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
- Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
- Phase I Study in RAD 001 Patients With Relapse AML
- Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
- Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007
- A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
- RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
- Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors
- Phase II Study of RAD001 Head and Neck Cancer
- Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
- Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas
- RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
- Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients
- Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction
- A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
- Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
- BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
- Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
- Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
- mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation
- Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients
- Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
- Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.
- CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation
- Everolimus in de Novo Heart Transplant Recipients
- Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
- Everolimus on CKD Progression in ADPKD Patients
- Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
- RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
- Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
- Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
- Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
- Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
- Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
- Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer
- Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
- Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
- Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol
- Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
- Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
- RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
- Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer
- Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
- Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
- Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
- Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
- Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program
- A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
- Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
- Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
- Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
- Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
- RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
- Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
- SORAVE - Sorafenib and Everolimus in Solid Tumors
- Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
- Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer
- Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
- Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
- Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
- Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
- Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
- Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
- Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
- Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
- Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer
- Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
- A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
- Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
- The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
- Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation
- Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
- Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
- RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
- Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
- Everolimus in Treating Patients With Recurrent Low-Grade Glioma
- RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
- Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
- A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study
- Trial of RAD001 in Triple Negative Metastatic Breast Cancer
- Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
- Everolimus in Treating Patients With Recurrent Low-Grade Glioma
- The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
- Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients
- RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
- Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
- Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients
- Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
- RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes
- Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
- RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
- Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
- Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A
- CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial
- Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
- Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)
- Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
- Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
- S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
- Treatment of Patients With RAD001 With Progressive Sarcoma
- Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia
- Doxil, Bevacizumab and Temsirolimus Trial
- A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
- RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
- Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
- Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
- Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
- Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
- Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing
- Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant
- RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
- Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
- Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery
- Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
- Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
- Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
- Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
- Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
- Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
- Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
- Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
- Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer
- RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
- RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
- Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
- A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
- Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
- Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
- Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up
- RAD001 Plus Bevacizumab in Metastatic Melanoma
- BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
- Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
- Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
- Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
- Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
- Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
- Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
- This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.
- This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus
- Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer
- Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
- Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
- Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- RAD001 in Advanced Hepatocellular Carcinoma
- Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
- Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen
- Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate
- Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
- Safe Renal Function In Long Term Heart Transplanted Patients
- Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients
- Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
- Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast
- Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
- Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients
- Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
- Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
- Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
- Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
- Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
- Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients
- Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion
- Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
- Safety of Everolimus and Pemetrexed in Lung Cancer Patients
- Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
- Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
- Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
- Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
- Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors
- Shift to Everolimus (RAD) Kidney Sparing Study
- Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
- Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
- Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
- Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
- RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
- A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
- Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation
- Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
- Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
- Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
- Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
- Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
- Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation
- Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
- Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease
- SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus
- A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
- Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
- S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.
- Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus
- Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
- Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
- Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
- Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection
- Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation
- Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
- RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency
- Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
- Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
- Polymorphism of the Cytochrome P450-system in Renal Transplants
- Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
- Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
- Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
- ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
- Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients
- Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen
- Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
- Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy
- Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients
- Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients
- Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients
- Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients
- A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
- Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus
- RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
- AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
- Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
- Everolimus in Treating Patients With Stage IV Melanoma
- Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
- Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
- Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
- Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
- RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
Clinical trials list
click for details